Independent Innovator and Repurposing Act

H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisions H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H,R, 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions H.R. 5233, Trade Secrets Protection Act of 2014: Provisions related to trade secrets S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S.2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition S. 2267, Defend Trade Secrets Act of 2014: Provisions related to trade secrets Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act Issues related to biopharmaceutical economic incentives and intellectual property

Client expense: $3,680,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

S.1720, the Patent Transparency and Improvements Act of 2013 H.R. 4287, S. 2150, the Independent Innovator and Repurposing Act H.R. 3309, the Innovation Act H.R. 1278, the Non-Disparagement of Native American Persons of Peoples in Trademark Registration Act of 2013H.R. 4103, the American Royalties Too Act H.R. 4287, S. 2150, the Independent Innovator and Repurposing Act H.R. 3309, the Innovation Act H.R. 5108, to establish the USPTO Law School Clinic Certification Program H.R. 5233, the Trade Secrets Protection Act of 2014. S. 2267, the Defend Trade Secrets Act of 2014.

Client expense: $210,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Legal Services Corporation, Library of Congress (LOC), Natl Security Agency (NSA), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Trade Representative (USTR), White House Office

Issues related to independent inventors and opportunities regarding the repurposing of biologics. H.R. 4287/S. 2150 - Independent Innovator Repurposing Act - focused on ensuring that independent researchers and physicians are able to see through repurposing research for certain biologic medications.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2582 - PATENT Jobs Act; provisions related to patent user fees H.R. 2605 - Manufacturing Innovation in America Act of 2013; provisions related to patent tax boxes H.R. 2639 - Patent Litigation and Innovation Act; patent litigation proposols H.R. 2766 - STOP Act; provisions related to business method patents H.R. 3116 - MODDERN Cures Act of 2013; Provisions related to exclusivity H.R. 3309 - Innovation Act; provisions related to patent litigation reform H.R. 3349 - Innovation Protection Act; provisions related to PTO fee diversion H.R. 3540 - Demand Letter Transparency Act; provisions related to patent demand letters H.R. 3709 - Protecting Consumer Access to Generic Drugsprovisions related to patent settlements H.R. 4287 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements S. 866 - Patent Quality Improvement Act of 2013; Business methods patents provisions S. 1013 - Patent Abuse Reduction Act of 2013; provisions related to patent litigation reform S. 1612 - Patent Litigation Integrity Act; Patent litigation provisions including bonding S. 1720 - Patent Transparency and Improvements Act S. 2049 - Transparency in Assertion of Patents Act; Provisions related to patent demand letters S. 2150 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S. 2196 - Patent Fee Integrity Act; patent fee diversion prohibition No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Intellectual property issues; Additional data exclusivity request that was part of 21st Century Cures submission

Funding for National Institutes of Health Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015Biosimilars Colombia Biologics Regulations Naming Implementation of Affordable Care Act Interchangeability and Pharmacy Substitution Funding for Centers for Disease Control and Prevention Vaccine Programs Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015 Vaccine Access/Financing Adult Immunization (Senate Discussion Draft) 340B Drug Pricing Program Implementation of Affordable Care Act Program Implementation & Oversight Departments of Labor, HHS, Education and Related Agencies Appropriations Act for FY 2015 Drug Importation H.R. 4660: Commerce, Justice, Science and Related Agencies Appropriations Act for FY 2015 Funding for FDA Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2015 Independent Payment Advisory Board Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2015 Reimbursement for Innovative Products Medicare Part B Physician-Administered Products Medicare Part D Prescription Drug Program Medicaid Pricing and Rebates Implementation of Affordable Care Act H.R. 1416: The Cancer Patient Protection Act of 2013 National Center for Advancing Translational Science (NCATS) (Non-Funding) Program Implementation Sequestration of PDUFA Fees Agriculture, Rural Development, FDA and Related Agencies Appropriations Act for FY 2015 HR 2725: Food and Drug Administration Safety Over Sequestration Act of 2013 S. 1413: FDA User Fee Protection Act TransPacific Partnership Regulatory Transparency Data and Intellectual Property Protections for Pharmaceuticals Transatlantic Trade & Investment Partnership Regulatory Harmonization/TransparencyDrug Evaluation and Review Implementation of the FDA Safety and Innovation Act 21st Century Cures Initiative Compassionate Use/Expanded Access FDA Proposed Rule on Changes to Drug Labeling Special Medical Use/Limited Population Drugs H.R. 4475: Compassionate Freedom of Choice Act H.R. 2090: The Patient Choice Act H.R. 3742: Antibiotic Development to Advance Patient Treatment Act of 2013 Orphan Drug Act Tax Credit Clinical Trial Data Sharing and Disclosure EU Policies Drug Manufacturing, Quality & Distribution Implementation of H.R. 3204: The Drug Quality and Security Act Compounding Sunshine Act Implementation Medicare Physician Payment Sustainable Growth Rate Formula S. 2110: Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014 Drug Repurposing H.R. 4287/S.2150: Independent Innovator and Repurposing Act

TransPacific Partnership Data and Intellectual Property Protections for PharmaceuticalsPatent Reform H.R. 3309: Innovation Act of 2013 S. 1013: Patent Abuse Reduction Act of 2013 S. 1720: Patent Transparency and Improvements Act of 2013 S. 866: Patent Quality Improvement Act of 2013 Targeting Rogue and Opaque Letters (TROL) Act of 2014 (Discussion Draft) FTC Regulation of Patent Demand Letters (Senate Commerce Committee Discussion Draft) Drug Repurposing H.R. 4287/S.2150: Independent Innovator and Repurposing Act Intellectual Property International Enforcement Compulsory Licensing India Issues Transatlantic Trade and Investment Partnership Intellectual Property Issues Patenting of Biological Inventions DNA Patenting and Licensing International Trade Commission Reform

Client expense: $2,110,000 · Firm income: Not reported

Issues relating to drug innovation, drug repurposing, intellectual property protections for innovators, and the Hatch-Waxman Act. The Independent Innovator and Repurposing Act, HR 4287; S 2150

Client expense: Not reported · Firm income: $15,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 22, Foreign Counterfeit Merchandise Prevention Act (entire bill) H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes (SHIELD) Act (entire bill)* H.R. 1663, Promoting Automotive Repair. Trade and Sales (PARTS) Act (entire bill)* S. 780, Promoting Automotive Repair. Trade and Sales (PARTS) Act (entire bill)*H.R. 2024, the End Anonymous Patents Act (entire bill)* H.R. 2236, the Promoting Startup Innovation Act (entire bill)* H.R. 2582, the PATENT Jobs Act (entire bill)* S. 214, Prohibiting the delay of generic drugs into the market (entire bill)* S. 662, Trade Facilitation and Trade Enforcement Reauthorization Act of 2013 (IP-related provisions)* S. 866, To Make Improvements to Transitional Program for Covered Business Method Patents (entire bill) S. 1013 Patent Abuse Reduction Act of 2013 (entire bill). S. 712, Patents for Humanity Program Improvement Act of 2013 (entire bill)* S. 1478 PACES Act (entire bill) H.R. 2766, Stopping the Offensive Use of Patents Act (entire bill)* H.R. 2639, Patent Litigation and Innovation Act of 2013 (entire bill)* H.R. 2466, Private Right of Action Against Theft of Trade Secrets Act of 2013 (entire bill) H.R. 3309, the Innovation Act (entire bill) H.R. 3349, Innovation Protection Act (entire bill)* S. 1720, Patent Transparency and Improvements Act (entire bill) S. 1612, Patent Litigation Integrity Act of 2013 (entire bill) H.R. 3713, to provide for the registration of marks consisting of a flag, coat of arms, or other insignia of the United States, or any State or local government (entire bill) S. 1770, Future of American Innovation and Research (FAIR) (entire bill)* S. 1816, to provide for the registration of marks consisting of a flag, coat of arms, or other insignia of the United States, or any State or local government (entire bill) S. 2146, Patent Fee Integrity Act (entire bill) S. 2049, Transparency in Assertion of Patents Act (entire bill) H.R. 4103, American Royalties Too Act (entire bill) S. 2045, American Royalties Too Act (entire bill) H.R. 4287, Independent Innovator and Repurposing Act (entire bill) S. 2150, Independent Innovator and Repurposing Act (entire bill) S. 2267, the Defend Trade Secrets Act (entire bill) H.R. 1123, Unlocking Consumer Choice and Wireless Competition Act (entire bill) S. 517, Unlocking Consumer Choice and Wireless Competition Act (entire bill)

H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity H.R. 3116, MODDERN Cures Act of 2013: Provisions related to exclusivity H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements H,R, 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration H.R. 4763, Trade Protection not Troll Protection Act: Patent and trade provisions S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S.2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2196, Patent Fee Integrity Act: Patent fee diversion prohibition Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues Draft legislation on demand letters Issues related to biopharmaceutical economic incentives and intellectual property

Issues related to independent inventors and opportunities regarding the repurposing of biologics. H.R. 4287/S. 2150 - Independent Innovator Repurposing Act - focused on ensuring that independent researchers and physicians are able to see through repurposing research for certain biologic medications.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2582, the Patents and Trademarks Emerging New Technology Jobs Act S.1612, the Patent Litigation Integrity Act of 2013 S.1720, the Patent Transparency and Improvements Act of 2013 H.R. 4103, the American Royalties Too ActS. 866, the "Patent Quality Improvement Act of 2013" S. 1013, the "Patent Abuse Reduction Act of 2013" S. 2049, the "Transparency in Assertion of Patents Act" H.R. 4287, S. 2150, the Independent Innovator and Repurposing Act H.R. 3309, the Innovation Act

Client expense: $260,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Federal Bureau of Investigation (FBI), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Justice, Dept of (DOJ), Labor, Dept of (DOL), Legal Services Corporation, Natl Security Agency (NSA), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Copyright Office, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office

H.R. 2582 - PATENT Jobs Act; provisions related to patent user fees H.R. 2605 - Manufacturing Innovation in America Act of 2013; provisions related to patent tax boxes H.R. 2639 - Patent Litigation and Innovation Act; patent litigation proposals H.R. 2766 - STOP Act; provisions related to business method patents H.R. 3116 - MODDERN Cures Act of 2013; provisions related to exclusivity H.R. 3309 - Innovation Act; provisions related to patent litigation reform H.R. 3349 - Innovation Protection Act; provisions related to PTO fee diversion H.R. 3540 - Demand Letter Transparency Act; provisions related to patent demand letters H.R. 3709 - Protecting Consumer Access to Generic Drugsprovisions related to patent settlements H.R. 4287 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements S. 866 - Patent Quality Improvement Act of 2013; provisions related to business methods patents provisions S. 1013 - Patent Abuse Reduction Act of 2013; provisions related to patent litigation reform S. 1612 - Patent Litigation Integrity Act; Patent litigation provisions including bonding S. 1720 - Patent Transparency and Improvements Act S. 2049 - Transparency in Assertion of Patents Act; provisions related to patent demand letters S. 2150 - Independent Innovator and Repurposing Act; provisions related to patent term restoration S.2196 - Patent Fee Integrity Act; patent fee diversion prohibition No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Intellectual property issues; Additional data exclusivity request that was part of 21st Century Cures submission

Issues related to independent inventors and opportunities regarding the repurposing of biologics. H.R. 4287/S. 2150 - Independent Innovator Repurposing Act - focused on ensuring that independent researchers and physicians are able to see through repurposing research for certain biologic medications.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to drug innovation, drug repurposing, intellectual property protections for innovators; and the Hatch-Waxman Act. The Independent Innovator and Repurposing Act, S. 2150; HR 4287

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues relating to drug innovation, drug repurposing, intellectual property protections for innovators; and the Hatch-Waxman Act. The Independent Innovator and Repurposing Act, S. 2150; HR 4287

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

"H.R. 22, Foreign Counterfeit Merchandise Prevention Act (entire bill) "S. 866, To Make Improvements to Transitional Program for Covered Business Method Patents (entire bill) "S. 1013 Patent Abuse Reduction Act of 2013 (entire bill). "S. 1478 PACES Act (entire bill)H.R. 2466, Private Right of Action Against Theft of Trade Secrets Act of 2013 (entire bill) H.R. 3309, the Innovation Act (entire bill) S. 1720, Patent Transparency and Improvements Act (entire bill) S. 1612, Patent Litigation Integrity Act of 2013 (entire bill) H.R. 3713, to provide for the registration of marks consisting of a flag, coat of arms, or other insignia of the United States, or any State or local government (entire bill) S. 1816, to provide for the registration of marks consisting of a flag, coat of arms, or other insignia of the United States, or any State or local government (entire bill) S. 2146, Patent Fee Integrity Act (entire bill) S. 2049, Transparency in Assertion of Patents Act (entire bill) H.R. 4103, American Royalties Too Act (entire bill) S. 2045, American Royalties Too Act (entire bill) H.R. 4287, Independent Innovator and Repurposing Act (entire bill) S. 2150, Independent Innovator and Repurposing Act (entire bill) Issues related to possible trade secret legislation

Client expense: $20,000 · Firm income: Not reported

H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation H.R. 2024, End Anonymous Patents Act: Patent owner information provisionsH.R. 2582, PATENT Jobs Act: Provisions related to patent user fees H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals H.R. 2766, STOP Act: Provisions related to business method patents H.R. 2985, Combination Drug Development Incentive Act of 2013 H.R. 3116, MODDERN Cures Act of 2013 H.R. 3309, Innovation Act: Provisions related to patent litigation reform H.R. 3349, Innovation Protection Act: PTO Fee Diversion H.R. 3540, Demand Letter Transparency Act of 2013: Provisions related to patent demand letters H.R. 3709, Protecting Consumer Access to Generic Drugs Act of 2013: Provisions related to patent settlements H.R. 4287, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions S. 627, Medical Innovation Prize Fund Act: Medical prize provisions S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions S. 1612, Patent Litigation Integrity Act of 2013: Patent litigation provisions including bonding S. 1720, Patent Transparency and Improvements Act of 2013: Provisions related to patent litigation, demand letters and the patent system S, 2049, Transparency in Assertion of Patents Act: Provisions related to patent demand letters S. 2150, Independent Innovator and Repurposing Act: Provisions related to patent term restoration S. 2146, Patent Fee Integrity Act: Patent fee diversion prohibition Biopharmaceutical innovation policy issues Biologics data protection issues Draft legislation on trade secret issues

H.R. 2582 - PATENT Jobs Act, provisions related to patent user fees H.R. 2605 - Manufacturing Innovation in America Act of 2013, provisions related to patent tax boxes H.R. 2639 - Patent Litigation and Innovation Act, patent litigation proposols H.R. 2766 - STOP Act, provisions related to business method patentsH.R. 3309 - Innovation Act, provisions related to patent litigation reform H.R. 3349 - Innovation Protection Act, provisions related to PTO fee diversion H.R. 3540 - Demand Letter Transparency Act H.R. 3709 - Protecting Consumer Access to Generic Drugs, provisions related to patent settlements H.R. 4287 - Independent Innovator and Repurposing Act, provisions related to patent term restoration S. 214 - The Preserve Access to Affordable Generics Act, provisions relating to patent settlements S. 504 - Fair and Immediate Release of Generic Drugs Act, provisions related to patent settlements S. 866 - Patent Quality Improvement Act of 2013, provisions related to business methods patents S. 1013 - Patent Abuse Reduction Act of 2013, provisions related to patent litigation reform S. 1612 - Patent Litigation Integrity Act, patent litigation provisions including bonding S. 1720 - Patent Transparency and Improvements Act S. 2049 - Transparency in Assertion of Patents Act, provisions related to patent demand letters S. 2150 - Independent Innovator and Repurposing Act, provisions related to patent term restoration S. 2196 - Patent Fee Integrity Act, patent fee diversion prohibition No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Biologics data protection issues No bill # assigned - Counterfeit drug issues

Client expense: $1,630,000 · Firm income: Not reported

Issues related to independent inventors and opportunities regarding the repurposing of biologics. H.R. 4287/S. 2150 - Independent Innovator Repurposing Act - focused on ensuring that independent researchers and physicians are able to see through repurposing research for certain biologic medications.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to independent inventors and opportunities regarding the repurposing of biologics. H.R. 4287/S. 2150 - Independent Innovator Repurposing Act - focused on ensuring that independent researchers and physicians are able to see through repurposing research for certain biologic medications.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE